John Kilhefner

John Kilhefner

John Kilhefner is Senior Managing Editor of the Luke Lango franchise, which includes Hypergrowth Investing, Innovation Investor, Crypto Investor Network, and more.
Kilhefner has contributed to media such as Benzinga, The Hill, Tip Ranks, Unwinnable, The Arcade Review, Five Out of Ten magazine, and ZAM. He has appeared in U.S. News and World Report, Kotaku, USA Today, and Game Developer.
He now runs his own creative agency focused on tech and cybersecurity, called Skellator, LLC.
Learn more here

Recent Articles

Why Care.com Inc (CRCM), Hershey Co (HSY) and Mobileye NV (MBLY) Are 3 of Today’s Best Stocks

Hershey (HSY) roared on a buyout bid (that it rejected), Care.com (CRCM) surged on a Google Capital stake and investors liked Mobileye's (MBLY) grouping with BMW and Intel.

Alphabet Inc (GOOG, GOOGL) Board Beefs Up Financial Chops With New Member

Alphabet just added its first African-American board member in Roger Ferguson, who will help GOOGL streamline its moonshot investments.

Wal-Mart Stores, Inc. (WMT) Takes Aim at Amazon Prime

Walmart's (WMT) expansion of its two-day shipping service, ShippingPass, and mobile payments service, Walmart Pay, could hurt Amazon (AMZN).

Why Tesaro Inc (TSRO), Clovis Oncology Inc (CLVS) and Twilio Inc (TWLO) Are 3 of Today’s Best Stocks

It was a good day for the stock market, but TSRO, CLVS and TWLO managed to stand out from the pack.

3 Consumer Stocks With Strong Dividends AND Growth

These consumer stocks should do well amid any more Brexit fears or other uncertainty thanks to generous dividends and substantial profit growth potential.

Apple Inc. (AAPL) Awarded Video-Shutdown Patent

Apple (AAPL) was awarded a patent to remotely shutdown your phone in video-sensitive venues. But there could be other implications.

Tesaro Inc (TSRO) Stock Soars 100% on Ovarian Cancer Drug Results

Tesaro Inc (NASDAQ:TSRO) is flying high on encouraging results from its ovarian cancer drug, niraparib, but it's still not FDA-approved.

Why Gilead Sciences, Inc. (GILD), Bank of America Corp (BAC) and Facebook Inc (FB) Are 3 of Today’s Best Stocks

The markets fared their best since the "Brexit" vote, but GILD, BAC and FB stood out the most as Tuesday's best stocks.

GILD Stock: FDA Greenlights Gilead Sciences, Inc. Hep-C Drug Epclusa

Gilead Sciences (GILD) stock is up big Tuesday after the FDA granted its drug, Epclusa, approval for use in chronic HCV patients.

Carnival Corp (CCL) Kills on Earnings, Announces $1B Stock Buyback

Carnival (NYSE:CCL) announced better-than-expected earnings for Q2, while a $1B buyback program competes with low-ball Q3 numbers.